Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer


Por: Blancas I, Olier C, Conde V, Bayo J, Herrero C, Zarcos-Pedrinaci I, Carabantes F, Baena-Canada J, Cruz J, Ruiz-Borrego M

Publicada: 19 feb 2021
Resumen:
Goals of endocrine therapy for advanced breast cancer (ABC) include prolonging survival rates, maintaining the quality of life, and delaying the initiation of chemotherapy. We evaluated the effectiveness of fulvestrant as first-line in patients with estrogen receptor (ER)-positive ABC with relapse during or after adjuvant anti-estrogenic therapy in real-world settings. Retrospective, observational study involving 171 postmenopausal women with ER-positive ABC who received fulvestrant as first-line between January 2011 and May 2018 in Spanish hospitals. With a median follow-up of 31.4 months, the progression-free survival (PFS) with fulvestrant was 14.6 months. No differences were seen in the visceral metastatic (14.3 months) versus non-visceral (14.6 months) metastatic subgroup for PFS. Overall response rate and clinical benefit rate were 35.2% and 82.8%. Overall survival was 43.1 months. The duration of the clinical benefit was 19.2 months. Patients with ECOG performance status 0 at the start of treatment showed a significant greater clinical benefit rate and overall survival than with ECOG 1-2. Results in real-world settings are in concordance with randomized clinical trials. Fulvestrant continues to demonstrate clinical benefits in real-world settings and appears be well tolerated as first-line for the treatment of postmenopausal women with ER-positive ABC.

Filiaciones:
Blancas I:
 Granada Univ, Hosp Univ Clin San Cecilio, Oncol Dept, Ave Conocimiento S-N, Granada 18006, Spain

 Granada Univ, Med Dept, Ave Conocimiento S-N, Granada 18006, Spain

Olier C:
 Hosp Univ Fdn Alcorcon, Oncol Dept, Calle Budapest 1, Madrid 28922, Spain

Conde V:
 Hosp Univ Virgen Las Nieves, Oncol Dept, Av Fuerzas Armadas S-N, Granada 18014, Spain

Bayo J:
 Hosp Juan Ramon Jimenez, Oncol Dept, Ronda Exterior Norte S-N, Huelva 21005, Spain

Herrero C:
 Hosp Prov Castellon, Oncol Dept, Av Dr Clara 19, Castellon de La Plana 12002, Spain

Zarcos-Pedrinaci I:
 Hosp Costa Sol, Oncol Unit, Km 187, Malaga 29603, Spain

Carabantes F:
 Hosp Reg Univ Malaga, Oncol Dept, Av Carlos Haya S-N, Malaga 29010, Spain

Baena-Canada J:
 Hosp Univ Puerta Mar, Oncol Dept, Cadiz 11009, Spain

 Inst Invest Innovac & Biomed Cadiz INiBICA, Cadiz 11009, Spain

Cruz J:
 Hosp Univ Canarias, Oncol Dept, Carretera Ofra S-N, Santa Cruz De Tenerife 38320, Spain

Ruiz-Borrego M:
 Hosp Univ Virgen Rocio, Oncol Dept, Av Manuel Siurot S-N, Seville 41013, Spain
ISSN: 20452322





Scientific Reports
Editorial
NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 11 Número: 1
Páginas:
WOS Id: 000621514400024
ID de PubMed: 33608590
imagen Green Published, gold

MÉTRICAS